Stockreport

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study [Yahoo! Finance]

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF the prespecified co-primary endpoints in the second late-stage study for Alzheimer's disease (AD). Simufilam is SAVA's proprietary, investigational oral small molecule t [Read more]